NRC Health (National Research Corporation) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This annual filing reports full-year results; it does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context
NRC Health sells primarily subscription-based analytics, research and software services to healthcare organizations. Its offerings cover patient and employee experience, consumer insights, reputation management and healthcare governance. The company reported one operating segment and employed 491 associates at year-end. U.S. customers generated $150.8 million of revenue; Canadian revenue was $0.8 million, and the Canadian office was closed in 2022.
Key financial metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $151.6 million | $148.0 million | +2.4% |
| Operating income | $46.5 million | $50.3 million | -7.4% |
| Operating margin | 30.7% | 34.0% | -3.3 percentage points |
| Net income | $31.8 million | $37.5 million | -15.1% |
| Diluted EPS | $1.27 | $1.46 | Lower |
| Cash from operating activities | $36.3 million | $46.3 million | -21.7% |
| Recurring contract value | $146.8 million | $150.9 million | -2.7% |
Subscription services contributed $142.0 million, or about 94% of revenue. Year-end cash and cash equivalents were $25.0 million, down from $54.4 million. Working capital surplus was $10.3 million, versus $33.3 million a year earlier. Total assets were $130.5 million and shareholders’ equity was $72.0 million.
Debt included a $22.3 million fixed-rate term loan at 5%, with monthly payments through May 2027. There was no balance on the $30 million revolving credit facility or the $75 million delayed-draw facility at year-end. The latter is restricted to permitted acquisitions or share repurchases. NRC Health reported compliance with its financial covenants.
Changes, outlook and material items
- Revenue growth reflected a $13.1 million increase in recurring revenue from existing U.S. clients, partly offset by lower new-customer recurring revenue, lower non-recurring revenue and the decline in Canadian revenue.
- Recurring contract value fell amid fewer new-client sales and a 2.0% decrease in client retention; management attributed part of the retention decline to focusing on core digital solutions.
- Operating costs rose faster than revenue, including higher compensation and retention costs, product-development investment, marketing and travel. Management cited inflation and elevated cost pressures expected to continue in 2023.
- Other expense included a $2.6 million foreign-currency translation loss recognized when the Canadian investment was substantially liquidated. The effective tax rate increased to 25.7% from 22.9%, partly due to reduced share-based compensation tax benefits and the non-deductible currency adjustment.
- Capital expenditures were $9.8 million in 2022, including $5.1 million for headquarters renovations. Estimated remaining renovation costs were $16.1 million in 2023 and $2.9 million in 2024, expected to be funded from operating cash flows.
- Cash returned to shareholders included $20.9 million of dividends declared and $27.6 million of share repurchases in 2022. The board authorized a new 2.5 million-share repurchase program in May 2022; 1,924,444 shares remained authorized at year-end. Future dividends and repurchases are discretionary.
- The company said existing cash, borrowing availability and operating cash flow should be sufficient for projected needs. It did not provide numeric revenue, earnings or margin guidance in the supplied filing text.
- Risks include annual contract renewals and client retention, competition and pricing pressure, healthcare-sector budget and regulatory changes, inflation, personnel attrition, technology or data-collection disruptions, cybersecurity and privacy incidents, and dependence on third-party providers. A third-party provider cyberattack in December 2022 temporarily suspended certain client services; the company reported no protected data was compromised or exfiltrated. A 2020 attack had also temporarily suspended services.
- Management and the auditor reported effective internal control over financial reporting. The auditor identified subscription-agreement terms and related revenue-system inputs as a critical audit matter. Management said ordinary-course claims and litigation were not expected to materially affect financial position, results or liquidity.
Investor verification priorities
- Verify renewal, retention and new-client sales trends, and how the decline in recurring contract value develops after year-end.
- Assess whether revenue growth can recover enough to offset rising labor, marketing and innovation costs and restore operating margin.
- Review cash-flow conversion, the reduced cash balance, and funding capacity for the remaining headquarters renovation spending, dividends and buybacks.
- Confirm debt amortization, credit-facility restrictions and covenant headroom, particularly if the company uses delayed-draw borrowing for repurchases or acquisitions.
- Track the impact of the Canadian wind-down, the one-time currency loss, and any further cybersecurity or third-party service interruptions.